Drug Profile
CAS 1609
Alternative Names: CAS-1609Latest Information Update: 04 Jul 2007
Price :
$50
*
At a glance
- Originator Cassella
- Class Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Vasodilators
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Heart failure
Most Recent Events
- 10 Aug 1998 No-Development-Reported for Angina pectoris in Germany (unspecified route)
- 10 Aug 1998 No-Development-Reported for Heart failure in Germany (unspecified route)
- 21 Sep 1995 Preclinical development for Heart failure in Germany (unspecified route)